Tatva Chintan Pharma Chem Ltd. Q3 FY26 Earnings Call Transcript Released
Tatva Chintan Pharma Chem reported Q3 FY26 revenue of ₹1,313 million (up 53% YoY) and EBITDA of ₹255 million (up 261% YoY). The company plans a new plant at Jolva, Dahej, with ₹250-275 crore capex, expected operational within 18 months. They anticipate ₹850-900 crore revenue in 2.5-3 years and 20-30% annual growth.
The release of the earnings call transcript provides detailed financial performance and future outlook, including significant capex plans and revenue growth projections, which are material to investors.
The company reported strong year-on-year growth in revenue and EBITDA, along with positive commentary on future outlook and strategic initiatives like new plant development.
Tatva Chintan Pharma Chem Limited has released the transcript of its earnings call held on January 21, 2026, to discuss the financial results for the quarter and nine months ended December 31, 2025. The company reported operating revenue of ₹1,313 million for Q3 FY26, a year-on-year growth of 53% and a sequential growth of 6%. EBITDA for the quarter stood at ₹255 million, reflecting a 261% year-on-year growth and a 15% improvement quarter-on-quarter.
Performance by category included: Phase Transfer Catalysts (₹279 million revenue, 5% sequential decline, 13% YoY growth), Electrolyte Salts (₹14 million revenue, 14% sequential and YoY growth), Pharma & Agro Intermediates and Specialty Chemicals (₹471 million revenue, 45% sequential growth, 86% YoY growth), and Structured Directing Agents (₹534 million revenue, 10% sequential decline, 65% YoY growth).
The company is progressing with its new plant at Jolva, Dahej, with ground-breaking expected in the current quarter. This facility is a key enabler for future growth, particularly for agro intermediates, and is expected to be operational within 18 months with a capex of approximately ₹250-275 crores. The company also anticipates achieving revenues of ₹850-900 crores within 2.5 to 3 years and projects a 20-30% year-on-year growth for FY26 and FY27, with EBITDA margins stabilizing around 20-22%.
What to do with a filing like this
Tatva Chintan Pharma Chem Limited filed this with the NSE as a statutory disclosure, categorised under concall transcript released. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Tatva Chintan Pharma Chem Limited. Read the original for the full detail.